InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,947.06
(
-2.32%
)
Post# of 29432
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

semi_infinite

Send PM Follow Ignore
Followers 14
Posts 3822
Boards Moderated 1
Alias Born 07/07/2002

semi_infinite

Re: semi_infinite post# 16129

Saturday, 03/10/2018 10:55:08 AM

Saturday, March 10, 2018 10:55:08 AM

Post# of 29432
Medical device salesman blog post his impression of TRXC progress relative to ISRG dominance.

https://www.medtechy.com/the-ticker/articles/2018/transenterix-earnings-what-did-we-learn

In the recent ISRG CC, CEO Guthart in Q&A talked about the cost sensitivity in Europe as a hurdle to adoption. That would be consistent Stifel's expectation that 2/3 of TRXC sales over the next 3 years will happen in EU region.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up